Cancer Letters
Volume 299, Issue 1 , Pages 22-28 , 18 December 2010

RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase

  • Kyung-Hun Lee

      Affiliations

    • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • These authors equally contributed to this work as first authors.
    • ,
  • Hyung-Seok Hur

      Affiliations

    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • These authors equally contributed to this work as first authors.
    • ,
  • Seock-Ah Im

      Affiliations

    • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Corresponding Author InformationCorresponding author at: Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehang-ro, Jongno-gu, Seoul, 110-744, Republic of Korea. Tel.: +82 2 2072 0850; fax: +82 2 762 9662.
    • ,
  • Juhee Lee

      Affiliations

    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Hwang-Phill Kim

      Affiliations

    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Young-Kwang Yoon

      Affiliations

    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Sae-Won Han

      Affiliations

    • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Sang-Hyun Song

      Affiliations

    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Do-Youn Oh

      Affiliations

    • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • ,
  • Tae-You Kim

      Affiliations

    • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine or College of Pharmacy, Seoul National University, Republic of Korea
    • ,
  • Yung-Jue Bang

      Affiliations

    • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    • Corresponding Author InformationCorresponding author at: Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehang-ro, Jongno-gu, Seoul, 110-744, Republic of Korea. Tel.: +82 2 2072 2390; fax: +82 2 762 9662.

Received 19 February 2010 ,Revised 22 June 2010 ,Accepted 22 July 2010.

References 

  1. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J. Clin. Oncol. 2005;23:5660–5667
  2. Chon HJ, Rha SY, Im CK, Kim C, Hong MH, Kim HR, et al. Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase ii trials. Cancer Res. Treat. 2009;41:196–204
  3. Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, et al. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br. J. Cancer. 2005;92:246–251
  4. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer. 2004;4:335–348
  5. Vignot S, Faivre S, Aguirre D, Raymond E. MTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 2005;16:525–537
  6. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004;100:657–666
  7. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism in growth and metabolism. Cell. 2006;124:471–484
  8. Sawyers CL. Will mTOR inhibitors make it as cancer drugs?. Cancer Cell. 2003;4:343–348
  9. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23:3151–3171
  10. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther. 2003;2:222–232
  11. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int. J. Cancer. 2005;117:376–380
  12. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int. J. Cancer. 2007;120:1803–1810
  13. Saga Y, Suzuki M, Mizukami H, Urabe M, Fukushima M, Ozawa K, et al. Enhanced expression of thymidylate synthase mediates resistance of uterine cervical cancer cells to radiation. Oncology. 2002;63:185–191
  14. Pandyra AA, Berg R, Vincent M, Koropatnick J. Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines. J. Pharmacol. Exp. Ther. 2007;322:123–132
  15. Xi Y, Nakajima G, Schmitz JC, Chu E, Ju J. Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genom. 2006;7:68
  16. Chu E, Callender MA, Farrell MP, Schmitz JC. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother. Pharmacol. 2003;1(Suppl. 52):S80–89
  17. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem. Pharmacol. 1995;49:1419–1426
  18. Kawate H, Landis DM, Loeb LA. Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine. J. Biol. Chem. 2002;277:36304–36311
  19. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995;55:1407–1412
  20. Leichman L, Leichman CG. Therapy of disseminated colorectal cancer: the emerging role of intratumoral molecular biology. Eur. J. Surg. 2001;(Suppl.):43–48
  21. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nonomura M, Nakao M, et al. Significance of thymidylate synthase activity in renal cell carcinoma. Clin. Cancer Res. 2003;9:1453–1460
  22. Nomura T, Nakagawa M, Fujita Y, Hanada T, Mimata H, Nomura Y. Clinical significance of thymidylate synthase expression in bladder cancer. Int. J. Urol. 2002;9:368–376
  23. Park JG, Yang HK, Kim WH, Chung JK, Kang MS, Lee JH, et al. Establishment and characterization of human gastric carcinoma cell lines. Int. J. Cancer. 1997;70:443–449
  24. Park JG, Kramer BS, Steinberg SM, Carmichael J, Collins JM, Minna JD, et al. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res. 1987;47:5875–5879
  25. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984;22:27–55
  26. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl. Cancer Inst. 1994;86:1517–1524
  27. Kim HP, Han SW, Kim SH, Im SA, Oh DY, Bang YJ, et al. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol. Cancer Ther. 2008;7:607–615
  28. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19:6680–6686
  29. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA. 2001;98:10314–10319
  30. Garber K. Rapamycin’s resurrection: a new way to target the cancer cell cycle. J. Natl. Cancer Inst. 2001;93:1517–1519
  31. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin. Cancer Res. 2004;10:1013–1023
  32. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500–1508
  33. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26:1932–1940
  34. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O’Reilly T, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005;120:747–759
  35. Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, et al. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. 2006;66:7639–7646
  36. Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, et al. MTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res. 2008;28:3801–3808
  37. Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, et al. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol. Ther. 2008;7:1377–1385

PII: S0304-3835(10)00379-4

doi: 10.1016/j.canlet.2010.07.020

Cancer Letters
Volume 299, Issue 1 , Pages 22-28 , 18 December 2010

Article Tools

* Image Usage & Resolution